Public knowledge and attitudes towards Human Papilloma Virus (HPV) vaccination

Walsh, Charlotte Devereaux; Gera, Aradhana; Shah, Meeraj; Sharma, Amit; Powell, Judy E; Wilson, Sue
January 2008
BMC Public Health;2008, Vol. 8 Issue 1, p368
Academic Journal
Background: Human Papilloma Virus (HPV) vaccine has undergone successful trials and has recently been approved for use for the primary prevention of cervical cancer. The aim of this study was to determine knowledge and attitudes towards HPV vaccination. Methods: Semi-structured interview and questionnaire delivered in a street survey. Standardised HPV-related statements used to measure HPV knowledge and attitudes to vaccination. The setting was three different areas of Birmingham, to target a mix of social class and ethnicity. The sample population was composed of 16-54 year olds. Results: A total of 420 participants were recruited. Poor knowledge of HPV and its links with cervical cancer were observed. 81% had a knowledge score of zero. Knowledge about HPV was associated with different ethnic group and socio-economic group. The majority (88%) of participants were in favour of vaccination, with 83.6% indicating that they would allow a child under their care to be vaccinated. Conclusion: Initial responses to the proposed HPV vaccination within the UK public are favourable. However, knowledge levels are poor and media and health professional promotion are required to raise awareness.


Related Articles

  • Dr. Lowy wins AAD 'innovation' award. Tsai, Allison // Dermatology Times;Apr2008, Vol. 29 Issue 4, p16 

    The article discusses the development and introduction of human papillomavirus (HPV) vaccine in the U.S. According to Douglas R. Lowy, chief of the Laboratory of Cellular Oncology, the HPV vaccine is preventive, not therapeutic. The Food and Drug Administration has approved the vaccine in 2006....

  • HPV vaccine coverage rates equal call to action for providers. Bocchini Jr., Joseph A. // Infectious Disease News;Sep2013, Vol. 26 Issue 9, p7 

    The article reports that no improvement was seen in the coverage rate for Human papillomavirus (HPV) for girls in 2012, which was revealed by the 2012 National Immunization Survey-Teen in a Morbidity and Mortality Weekly Report.

  • Human papillomavirus vaccine and behavioural disinhibition. Schuler, Christine L; Reiter, Paul L; Smith, Jennifer S; Brewer, Noel T // Sexually Transmitted Infections;Jun2011, Vol. 87 Issue 4, p349 

    Objectives: We sought to identify characteristics of parents who believe in sexual disinhibition and that Pap smears can safely be stopped after females receive the human papillomavirus (HPV) vaccine.Methods: We surveyed 647 parents of adolescent girls living in areas...

  • Vaccines for Papillomavirus (HPV) Infection. Rodríguez-Cerdeira, C.; Alba, A. // Open Dermatology Journal;2009, Vol. 3, p129 

    Prophylactic HPV vaccination of both quadrivalent and bivalent vaccines has already been approved in Spain and is gaining popularity among Spanish women. Other European countries show similar trends. With the use of vaccines against HPV, especially the tetravalent vaccine, in the short or...

  • Attitudes about human papillomavirus vaccine in young women. Kahn, Jessica A.; Rosenthal, Susan L.; Hamann, Tara; Bernstein, David I. // International Journal of STD & AIDS;May2003, Vol. 14 Issue 5, p300 

    Human papillomavirus (HPV) vaccines are under investigation, but little is known about attitudes regarding vaccination. The aims of this study were to identify attitudes about and intention to receive an HPV vaccine in young women using a theory-based model. Young women (n=52, mean age 25 years,...

  • Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®): Profile Report1. Siddiqui, M. Asif A.; Perry, Caroline M. // BioDrugs;2006, Vol. 20 Issue 5, p313 

    Darbepoetin alfa (Aranesp) is an analog of recombinant human erythropoietin (rHuEPO) produced using recombinant DNA technology. The high number of sialic acid moieties in darbepoetin alfa results in a prolonged half-life and enhanced in vivo biologic activity compared with rHuEPO (as...

  • Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix™]: Profile Report. Keam, Susan J; Harper, Diane M // BioDrugs;2008, Vol. 22 Issue 3, p205 

    The article focuses on the vaccines for Human Papillomavirus (HPV) types 16 and 18. It informs that a prophylactic vaccine against oncogenic HPV types is likely to be of value as a prevention strategy. It is stated that for long-term effect, a cervical cancer vaccine needs to lead to a strong...

  • Pricing Human Papillomavirus Vaccines Lessons from Italy. Garattini, Livio; Van De Vooren, Katelijne; Curto, Alessandro // PharmacoEconomics;2012, Vol. 30 Issue 3, p213 

    The article presents the author's views on the Human Papillomavirus (HPV) vaccine prices in Italy. He comments that the coverage of three screening programmes were listed by the Italian Ministry of Health (MoH) recently. He remarks on two linear regressions conducted to examine the correlation...

  • Majority of women positive about HPV vax for pre-teens.  // PharmacoEconomics & Outcomes News;8/9/2008, Issue 559, p6 

    The article discusses research on the attitudes of women towards human papillomavirus (HPV) vaccinations for pre-adolescents. It references a study by I. J. Korfage and colleagues published in the June 2008 issue of the "European Journal of Cancer." The attitudes of study participants towards...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics